Abstract

P-266 Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Regorafenib joins immune checkpoint inhibitors (ICIs) for previously ICIs plus TKIs failed advanced hepatocellular carcinoma (HCC) patients: A retrospective study.
Guoyong Han ... Chao Yang
Journal of Clinical Oncology | VOL. 40
Guoyong Han, et. al.Guoyong Han ... Chao Yang
01 Jun 2022
Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients.
Thomas Cheung Yau ... Tan To Cheung
Journal of Clinical Oncology | VOL. 37
Thomas Cheung Yau, et. al.Thomas Cheung Yau ... Tan To Cheung
01 Feb 2019
Efficacy and safety of regorafenib alone or in combinations for advanced hepatocellular carcinoma: A multicenter real-world study.
Haidong Zhu ... Qi Wang
Journal of Clinical Oncology | VOL. 40
Haidong Zhu, et. al.Haidong Zhu ... Qi Wang
01 Jun 2022
A phase II, randomized, controlled trial of nivolumab in combination with BMS-986253 or cabiralizumab in advanced hepatocellular carcinoma (HCC) patients.
Deirdre Jill Cohen ... Despina Siolas
Journal of Clinical Oncology | VOL. 38
Deirdre Jill Cohen, et. al.Deirdre Jill Cohen ... Despina Siolas
01 Feb 2020
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: ‘ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe’, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Re: Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]. Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4
Elio Mazzone ... Francesco Montorsi
Annals of Oncology | VOL. -
Elio Mazzone, et. al.Elio Mazzone ... Francesco Montorsi
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
View more papers